Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).
about
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyCIViC databaseClinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations.Utilizing protein structure to identify non-random somatic mutations.Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.A novel insertion mutation on exon 20 of epidermal growth factor receptor, conferring resistance to erlotinib.Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation.Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significanceEffects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC.Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review.S768I Mutation in EGFR in Patients with Lung Cancer.Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report.Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer
P2860
Q26744284-0E5260AC-15A6-4DFE-A6F5-B7AC3E536FB7Q27612411-C0A37831-2DF8-49FA-86A0-44AF64218312Q27853109-7622D888-3F31-4491-801F-086D7E85D741Q30360645-9A3FF14A-6EB6-45BE-BA58-725EE0239113Q30431811-8E283BF8-6A11-448B-9D27-32CB02AB0AEAQ33682941-9A93765C-F809-4C7A-91B8-D41B252E4E02Q34041701-B25C3C2D-517E-4767-9C8C-5D1B82F58561Q34131441-71FFEE66-5BEA-475B-9258-152D55C36C5CQ35541933-6863B1D1-385F-4D30-AD2A-4324B3C838E8Q36491122-61F3B901-96BE-46C0-B3A0-4FA00B7F0682Q36503084-16B8D278-039A-4EA5-833B-C92DC7C61608Q36558808-971E8CB1-9B24-4345-9FCA-CA662D01F81EQ37094986-F075541C-0E10-4169-9FA4-EC29310E5740Q37697306-8131A72D-AFCC-40DB-B110-C09A8EC22AAEQ38319572-223D96AE-CF84-4520-A5DB-C6B5E3EF4C52Q38931077-50FC4CFD-88D0-441D-AB4F-C8B837A46270Q39745401-1CADB451-45F8-4794-9261-9AF163FBDAE8Q54979668-9ED3C998-2539-45C1-A3F8-3FDC7B829AC3Q58786408-7B043769-42E9-414C-B567-7BBB2BBA731A
P2860
Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Good clinical response to gefi ...... AGC > ATC in exon 20 (S768I).
@ast
Good clinical response to gefi ...... AGC > ATC in exon 20 (S768I).
@en
Good clinical response to gefi ...... AGC > ATC in exon 20 (S768I).
@nl
type
label
Good clinical response to gefi ...... AGC > ATC in exon 20 (S768I).
@ast
Good clinical response to gefi ...... AGC > ATC in exon 20 (S768I).
@en
Good clinical response to gefi ...... AGC > ATC in exon 20 (S768I).
@nl
prefLabel
Good clinical response to gefi ...... AGC > ATC in exon 20 (S768I).
@ast
Good clinical response to gefi ...... AGC > ATC in exon 20 (S768I).
@en
Good clinical response to gefi ...... AGC > ATC in exon 20 (S768I).
@nl
P2093
P2860
P3181
P356
P1476
Good clinical response to gefi ...... AGC > ATC in exon 20 (S768I).
@en
P2093
Kaoru Irisa
Katsuhiro Masago
Masataka Ichikawa
Michiaki Mishima
Shiro Fujita
Tadashi Mio
Yung Hak Kim
P2860
P304
P3181
P356
10.1093/JJCO/HYQ087
P577
2010-11-01T00:00:00Z